NASH and Fibrosis - CPL | US
Offer Details: | |
|---|---|
| Offer Name: | NASH and Fibrosis - CPL | US |
| Payout: | $70.00 / CPA |
| Preview: | Preview Landing Page |
| Categories: | Ecommerce |
| Network: | DYNU IN MEDIA |
| Last Updated: | May 18, 2025 |
| Countries: | US |
Age Range: 18-80
Gender: Any
Study Description: This study is testing an investigational injectable medication for the treatment of Non-Alcoholic Steatohepatitis (NASH), newly known as Metabolic Dysfunction Associated Steatohepatitis (MASH) and Fibrosis. Participants will receive either the study medication or a placebo as an injection, either weekly or bi-weekly, for 3 years. Additional procedures and tests will include vital signs, physical exams, laboratory tests, liver biopsies, FibroScans®and electrocardiograms (ECGs). Total participation will last approximately 3 years and 4 months, including 14 doctor’s visits and 4 phone visits throughout the study. Eligibility for the study will be determined by the study doctor following completion of all screening tests and procedures at an in-person screening visit to the clinic. Trial-related procedures and study medication will be provided at no cost.
Qualifications:
- Must be in stage 2, 3, or 4 Fibrosis
- Cannot have experienced significant weight gain or weight loss in the last 3 months (5% of body weight)
Qualifications:
- Cannot be diagnosed with asthma, lung fibrosis, pulmonary hypertension, interstitial lung disease, or sarcoidosis
PROOF REQUIRED
Mailer Access: Key: https://www.affiliateaccesskey.com/m-dzkm-s96-7b3bddaa5ec9115a077e95bf090d9865
Optout Link: https://www.twonailhall.com/o-dzkm-s96-bfc2ae7cf26f323c5398c1b008c6fabe
Gender: Any
Study Description: This study is testing an investigational injectable medication for the treatment of Non-Alcoholic Steatohepatitis (NASH), newly known as Metabolic Dysfunction Associated Steatohepatitis (MASH) and Fibrosis. Participants will receive either the study medication or a placebo as an injection, either weekly or bi-weekly, for 3 years. Additional procedures and tests will include vital signs, physical exams, laboratory tests, liver biopsies, FibroScans®and electrocardiograms (ECGs). Total participation will last approximately 3 years and 4 months, including 14 doctor’s visits and 4 phone visits throughout the study. Eligibility for the study will be determined by the study doctor following completion of all screening tests and procedures at an in-person screening visit to the clinic. Trial-related procedures and study medication will be provided at no cost.
Qualifications:
- Must be in stage 2, 3, or 4 Fibrosis
- Cannot have experienced significant weight gain or weight loss in the last 3 months (5% of body weight)
Qualifications:
- Cannot be diagnosed with asthma, lung fibrosis, pulmonary hypertension, interstitial lung disease, or sarcoidosis
PROOF REQUIRED
Mailer Access: Key: https://www.affiliateaccesskey.com/m-dzkm-s96-7b3bddaa5ec9115a077e95bf090d9865
Optout Link: https://www.twonailhall.com/o-dzkm-s96-bfc2ae7cf26f323c5398c1b008c6fabe
DYNU IN MEDIA
DYNU IN MEDIA is a super match CPA/CPL network for earning money online that provides you with all techniques allowing you to monetize your traffic in all channels. We guarantee outstanding support to our publishers. Our devoted team with experience in the affiliate marketing industry will give you full-assist, direct offers in a wide-ranging variety of verticals and top GEOs, and a flexible payment schedule of NET15 & NET30. Hitting more than 20,000 leads generated daily for over 200 influential clients, along with an increasing number of HQ publishers to 300 and more, DYNU IN MEDIA is taking high pride in our professionalism and high integrity.
